These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 38416493)

  • 1. Knowledge, Preference, and Adverse Effects of Xylazine Among Adults in Substance Use Treatment.
    Hochheimer M; Strickland JC; Rabinowitz JA; Ellis JD; Dunn KE; Huhn AS
    JAMA Netw Open; 2024 Feb; 7(2):e240572. PubMed ID: 38416493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug use practices and wound care experiences in the age of xylazine adulteration.
    Jawa R; Ismail S; Shang M; Murray S; Murray-Krezan C; Zheng Y; Mackin S; Washington K; Alvarez P; Dillon J; McMurtrie G; Stein M; Walley A; Liebschutz JM
    Drug Alcohol Depend; 2024 Oct; 263():112390. PubMed ID: 39173221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Syringe services program staff and participant perspectives on changing drug consumption behaviors in response to xylazine adulteration.
    Eger WH; Plesons M; Bartholomew TS; Bazzi AR; Hauschild MH; McElrath CC; Owens C; Forrest DW; Tookes HE; Crable EL
    Harm Reduct J; 2024 Aug; 21(1):162. PubMed ID: 39210359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The emerging of xylazine as a new drug of abuse and its health consequences among drug users in Puerto Rico.
    Reyes JC; Negrón JL; Colón HM; Padilla AM; Millán MY; Matos TD; Robles RR
    J Urban Health; 2012 Jun; 89(3):519-26. PubMed ID: 22391983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Xylazine awareness and attitudes among people who use drugs in Ohio, 2023-2024.
    Michaels NL; Bista S; Short Mejia A; Hays H; Smith GA
    Harm Reduct J; 2024 Oct; 21(1):182. PubMed ID: 39402530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protective or potentially harmful? Altering drug consumption behaviors in response to xylazine adulteration.
    Eger WH; Plesons M; Bartholomew TS; Bazzi AR; Hauschild MH; McElrath CC; Owens C; Forrest DW; Tookes HE; Crable EL
    Res Sq; 2024 Aug; ():. PubMed ID: 39149447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reported Xylazine Use Among Adults Aged ≥18 Years Evaluated for Substance Use Treatment - United States, July 2022-September 2023.
    Jiang X; Connolly S; Strahan AE; Rivera Blanco L; Mikosz CA; Guy GP; Dowell D
    MMWR Morb Mortal Wkly Rep; 2024 Jul; 73(26):594-599. PubMed ID: 38959171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Commentary on Copeland et al.: Does xylazine in the United Kingdom foreshadow a European synthetic polysubstance drug crisis?
    Friedman JR
    Addiction; 2024 Jul; 119(7):1310-1312. PubMed ID: 38570907
    [No Abstract]   [Full Text] [Related]  

  • 9. The first drug-related death associated with xylazine use in the UK and Europe.
    Rock KL; Lawson AJ; Duffy J; Mellor A; Treble R; Copeland CS
    J Forensic Leg Med; 2023 Jul; 97():102542. PubMed ID: 37236142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Xylazine Complicating Opioid Ingestions in Young Children.
    Deutsch SA; De Jong AR
    Pediatrics; 2023 Jan; 151(1):. PubMed ID: 36550066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Iatrogenic disease: an epidemiologic perspective.
    Sartwell PE
    Int J Health Serv; 1974; 4(1):89-93. PubMed ID: 4829900
    [No Abstract]   [Full Text] [Related]  

  • 12. Qualitative and quantitative characteristics of xylazine-associated deaths detected using a post-mortem toxicology testing program.
    Vohra V; Stroh-Steiner GK; Jones P
    Clin Toxicol (Phila); 2023 Dec; 61(12):1040-1046. PubMed ID: 38088581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Xylazine Adulteration in Illicit Fentanyl: A Threat to Public Health.
    Marshall SA; Nelson LA
    J Pharm Pract; 2024 Sep; ():8971900241279635. PubMed ID: 39237081
    [No Abstract]   [Full Text] [Related]  

  • 14. Psychoactive substance use prior to the development of iatrogenic opioid abuse: A descriptive analysis of treatment-seeking opioid abusers.
    Cicero TJ; Ellis MS; Kasper ZA
    Addict Behav; 2017 Feb; 65():242-244. PubMed ID: 27544696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacology and toxicology of xylazine: quid novum?
    Malaca S; Pesaresi M; Kapoor A; Berretta P; Busardò FP; Pirani F
    Eur Rev Med Pharmacol Sci; 2023 Aug; 27(15):7337-7345. PubMed ID: 37606142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Xylazine in human tissue and fluids in a case of fatal drug abuse.
    Poklis A; Mackell MA; Case ME
    J Anal Toxicol; 1985; 9(5):234-6. PubMed ID: 4057964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Xylazine: Pharmacology Review and Prevalence and Drug Combinations in Forensic Toxicology Casework.
    Kacinko SL; Mohr ALA; Logan BK; Barbieri EJ
    J Anal Toxicol; 2022 Oct; 46(8):911-917. PubMed ID: 35770859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigating opioid preference to inform safe supply services: A cross sectional study.
    Ferguson M; Parmar A; Papamihali K; Weng A; Lock K; Buxton JA
    Int J Drug Policy; 2022 Mar; 101():103574. PubMed ID: 35007878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Xylazine Use Among People Who Inject Drugs, Philadelphia 2022.
    Tan M; Nassau T; Kuncio D; Higgins D; Teixeira da Silva D; Tomlinson D; Brady KA
    J Addict Med; 2024 Mar-Apr 01; 18(2):194-200. PubMed ID: 38289240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [I. Obligatory continuing education for all college graduate cadres in public and social health care facilities 1972. Selective subjects for physicians, dentists and pharmacists. Drug abuse and iatrogenic diseases (liver, kidney, blood). Iatrogenic liver diseases].
    Stein W
    Z Arztl Fortbild (Jena); 1972 Jul; 66(13):653-4. PubMed ID: 4636962
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.